Check out the
essentials

Arrows

Scroll through facts and figures for alprolix

Proven Protection
from bleeds*


People infusing prophylactically experienced a median of 1 or fewer spontaneous bleeds per year.

Scroll down for additional pivotal trial details. >

100% Target Joint Resolution
in 37 Patients

On a 10-day dosing regimen, adults and adolescents experienced a median annual joint bleed rate of 0.36 (n=26).

37/37 patients with target joints at the baseline of the B-LONG study achieved target joint resolution with ALPROLIX. These subjects had ≥12 months of consecutive follow-up time and did not undergo joint surgery within 12 months of the start of follow-up.

In our clinical trial, adults and adolescents on a 7-day dosing interval, had a median annual joint bleed rate of 1.11 (n=61).

A target joint is defined as a major joint with 3 or more bleeding episodes in a consecutive 6-month period. Target joint resolution is defined as 2 or less spontaneous bleeds in a 12-month period.

37/37 patients with target joints at the baseline of the B-LONG study achieved target joint resolution with ALPROLIX. These subjects had ≥12 months of consecutive follow-up time and did not undergo joint surgery within 12 months of the start of follow-up.

A target joint is defined as a major joint with 3 or more bleeding episodes in a consecutive 6-month period. Target joint resolution is defined as 2 or less spontaneous bleeds in a 12-month period.

Once-weekly Prophy GROUP In a clinical study, people infusing on a once-weekly prophy regimen with ALPROLIX experienced a median annual spontaneous bleed rate (AsBR) of 1.0 bleed per year. The overall median annual bleed rate (ABR) was 3 bleeds per year. (n=61)

individualized prophy group People who started infusing on a 10-day prophy regimen with ALPROLIX experienced a median AsBR of 0.9 bleeds per year. The overall median ABR was 1.4 bleeds per year. (n=26)

*ALPROLIX has been proven to help patients prevent bleeding episodes using a prophylaxis regimen.

Interested in extending? This may help get you started.

" "I recommend ALPROLIX to patients many times because I've seen it be successful.

Dr. Guillermo De Angulo, Hematology-Oncologist.

Actual healthcare professional being compensated by Sanofi Genzyme. Not an Actor.

One Infusion,
Excellent Possibilities

A total of 636 bleeding episodes occurred in 114 people in the different groups of the study, excluding the surgery group.
These bleeds were treated successfully with ALPROLIX.

Alprolix is the only factor IX with two starting prophy dose options

The recommended starting prophylaxis regimens are either 50 IU/kg once weekly, or 100 IU/kg once every 10 days. Dosing regimen can be adjusted based on individual response.

Children under 12 years of age may have higher Factor IX body weight-adjusted clearance, shorter half-life, and lower recovery. Higher dose per kilogram body weight or more frequent dosing may be needed.

No matter which starting dose
you choose, you may be able
to extend

In the clinical trial, more than half of the people who started on an every-10-day dosing regimen at 100 IU/kg extended to 14 days or longer between infusions.

54% of people in the individualized prophy arm extended to ≥14-day dosing. The overall median dosing interval on study was 12.5 days. The median interval during the last six months in 26 subjects who were on study for at least nine months was 13.8 days.

Still treating on-demand?
Rethink your routine

Around 3 preventative
infusions per month

87% fewer bleeds
vs on-demand treaters

That's less than
one bleed per year

In the individualized prophylaxis group, 29 people were initially given 100 IU/kg every 10 days and their intervals were adjusted to maintain desired Factor IX levels.

Calculated with a negative binomial model, patient infusing on an individualized prophylaxis regimen versus those treating on-demand.

GET THE DETAILS
BEHIND ALPROLIX

Well, there you have it. The highlights of ALPROLIX: protection, bleed control, and extended prophy dosing. Still want to learn more? Explore the links below to move onto the next level of ALPROLIX knowledge.

Patient Stories


Watch how switching to ALPROLIX impacted the lives of people with hemophilia B.

Watch their stories

The details


Get more in-depth information about ALPROLIX and what it can mean for your hemophilia therapy.

Learn More

Talk To Your Doctor


Make the most of your doctor visits. Download our discussion guide so you ask the right questions and cover the right topics.

Get prepared
×

INDICATIONS: ALPROLIX® [Coagulation Factor IX (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in people with hemophilia B. Hemophilia B is also called congenital Factor IX deficiency. Your healthcare provider may give you ALPROLIX when you have surgery.

important safety information and indications 

IMPORTANT SAFETY INFORMATION
Do not use ALPROLIX if you are allergic to ALPROLIX or any of the other ingredients in ALPROLIX.

Tell your healthcare provider if you have or have had any medical problems, take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines, have any allergies and all your medical conditions, including if you are pregnant or planning to become pregnant, are breastfeeding or have been told you have inhibitors (antibodies) to Factor IX.

Common side effects of ALPROLIX include headache, abnormal sensation in the mouth, and pain in your side with blood in your urine, which may be a sign of clot formation in the urinary collecting system. These are not all the possible side effects of ALPROLIX. Talk to your healthcare provider right away about any side effect that bothers you or does not go away, and if bleeding is not controlled using ALPROLIX.

Allergic reactions may occur with ALPROLIX. Call your healthcare provider or get emergency treatment right away if you have any of the following symptoms: hives, chest tightness, wheezing, difficulty breathing, or swelling of the face.

Your body can also make antibodies called "inhibitors" against ALPROLIX, which may stop ALPROLIX from working properly.

ALPROLIX may increase the risk of formation of abnormal blood clots in your body, especially if you have risk factors for developing blood clots. Call your healthcare provider or seek emergency care if you have symptoms of a possible abnormal blood clot, which may include: chest pain, difficulty breathing, unexpected swelling of an arm or leg with or without pain or tenderness.

INDICATIONS
ALPROLIX® [Coagulation Factor IX (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in people with hemophilia B. Hemophilia B is also called congenital Factor IX deficiency. Your healthcare provider may give you ALPROLIX when you have surgery.

indications and important facts about alprolix 

IMPORTANT SAFETY INFORMATION
Do not use ALPROLIX if you are allergic to ALPROLIX or any of the other ingredients in ALPROLIX.

Tell your healthcare provider if you have or have had any medical problems, take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines, have any allergies and all your medical conditions, including if you are pregnant or planning to become pregnant, are breastfeeding or have been told you have inhibitors (antibodies) to Factor IX.

Common side effects of ALPROLIX include headache, abnormal sensation in the mouth, and pain in your side with blood in your urine, which may be a sign of clot formation in the urinary collecting system. These are not all the possible side effects of ALPROLIX. Talk to your healthcare provider right away about any side effects that bothers you or does not go away, and if bleeding is not controlled using ALPROLIX.

Allergic reactions may occur with ALPROLIX. Call your healthcare provider or get emergency treatment right away if you have any of the following symptoms: hives, chest tightness, wheezing, difficulty breathing, or swelling of the face.

Your body can also make antibodies called "inhibitors" against ALPROLIX, which may stop ALPROLIX from working properly.

ALPROLIX may increase the risk of formation of abnormal blood clots in your body, especially if you have risk factors for developing blood clots. Call your healthcare provider or seek emergency care if you have symptoms of a possible abnormal blood clot, which may include: chest pain, difficulty breathing, unexpected swelling of an arm or leg with or without pain or tenderness.

INDICATIONS
ALPROLIX® [Coagulation Factor IX (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in people with hemophilia B. Hemophilia B is also called congenital Factor IX deficiency. Your healthcare provider may give you ALPROLIX when you have surgery.

Please see Full Prescribing Information

MANUFACTURED BY
Bioverativ Therapeutics Inc.
Waltham, MA 02451 USA
U.S. License #2078

Questions?

1-855-MYALPROLIX (1-855-692-5776)

Monday-Friday, 8am-8pm, EST

© 2020 Genzyme Corporation. All rights reserved. ALPROLIX is a registered trademark of Bioverativ Therapeutics Inc., a Sanofi company.

FIX-US-1274 V4 09/19

© 2020 Genzyme Corporation. All rights reserved. ALPROLIX is a registered trademark of Bioverativ Therapeutics Inc., a Sanofi company.

FIX-US-1274 V4 09/19

Questions?

1-855-MYALPROLIX (1-855-692-5776)

Monday-Friday, 8am-8pm, EST